Utah Medical Products, Inc. — Q2 2012 Form 10-Q
Business context and reporting period: The company manufactures and markets primarily single-use specialty medical devices. This unaudited report covers the three and six months ended June 30, 2012; financial amounts are in thousands of dollars except per-share data. Comparisons are with the corresponding 2011 periods.
Financial performance
| Metric | Q2 2012 | Q2 2011 | First half 2012 | First half 2011 |
|---|---|---|---|---|
| Net sales | $10,025 | $10,377 | $21,230 | $17,170 |
| Gross profit | $6,071 | $6,260 | $12,809 | $9,969 |
| Operating income | $3,552 | $3,233 | $7,667 | $5,390 |
| Net income | $2,401 | $1,982 | $5,190 | $3,319 |
| Diluted EPS | $0.65 | $0.54 | $1.41 | $0.91 |
| Gross margin | 60.6% | 60.3% | 60.3% | 58.1% |
| Operating margin | 35.4% | 31.2% | 36.1% | 31.4% |
| Net margin | 24.0% | 19.1% | 24.4% | 19.3% |
Cash flow and liquidity: First-half operating cash flow was $6,537, versus $4,447 in 2011. Investing activities used $134, while financing activities used $5,021, including $5,221 of debt repayments and $878 of dividends paid. Cash increased $1,378 to $7,913. At June 30, current assets were $18,652 and current liabilities were $10,750, producing working capital of $7,901 and a current ratio of about 1.7.
Debt and balance sheet: Notes payable totaled $16,560, comprising $5,406 current and $11,154 long-term, down from $21,672 at December 31, 2011. Total liabilities were $31,332 and equity was $45,548; the company reported a total debt ratio of 41%, versus 47% at year-end. Debt was primarily related to the 2011 Femcare acquisition. The company stated it was in compliance with all loan covenants; all notes payable are scheduled to be repaid by April 2016.
Material changes and management commentary
- Q2 sales declined 3.4%, while operating income rose 9.9% and net income rose 21.1%. Management attributed softer Q2 sales to a stronger U.S. dollar and continued weak hospital device utilization. Lower selling and administrative costs and reduced interest expense supported profit growth.
- First-half sales rose 23.7%, operating income 42.2%, and net income 56.4%. The comparison is materially affected by Femcare, acquired March 18, 2011: 2011 results included Femcare for only part of the first half, whereas 2012 included a full six months. Femcare contributed $8,862 of first-half 2012 revenue and $2,326 of after-tax income. The filing’s pro forma comparison shows first-half revenue of $21,230 in 2012 versus $21,089 in 2011; pro forma 2011 net income was $4,064 and excluded specified acquisition-related costs.
- Q2 international sales fell 7%; first-half international sales increased 31% and represented 51% of sales. Product-category results were mixed: first-half gynecology/electrosurgery sales rose 56%, while obstetrics fell 14% and neonatal fell 5%.
- First-half gross margin improved, which management attributed mainly to a product mix shift toward higher-margin Femcare products. The effective income tax provision declined to 29.6% from 34.9% in the first half, reflecting a greater share of profits in lower-tax jurisdictions and a lower UK tax rate.
- Goodwill and other intangible assets remained significant at $49,696 combined, about 65% of total assets. First-half amortization of acquired identifiable intangibles was $1,305.
Outlook, risks and contingencies
Management said first-half performance was consistent with its 2012 objectives: realize Femcare integration synergies, begin direct sales to Irish end users, introduce three gynecology products, sustain financial performance, and use cash generation to repay debt while maintaining dividends and considering repurchases when shares appear undervalued. Planned capital spending for the rest of 2012 was expected to be below depreciation. No earnings or revenue guidance was provided.
Risks highlighted include foreign-exchange fluctuations (the company does not use separate hedging transactions), medical-device regulation and approval delays, U.S. healthcare reform and the scheduled 2013 device excise tax, hospital purchasing bureaucracy and GPO pressures, product liability, reliance on overseas distributors, acquisition-related debt, and loss of key employees. Management reported no litigation it believed could materially affect results, no subsequent events requiring disclosure, and no warranty reserve based on its estimate that existing obligations were immaterial. Disclosure controls were deemed effective, with no material control changes reported.
Important facts for investors to verify
- How much first-half growth reflects full-period Femcare consolidation versus underlying organic growth; compare reported results with the filing’s pro forma figures and acquisition contribution.
- Whether Q2 sales weakness, foreign-exchange pressure and subdued hospital utilization persist, particularly in obstetrics and neonatal products.
- Progress in debt reduction, covenant compliance and scheduled repayments, including sensitivity to interest rates and currency movements.
- Sustainability of margins and the lower effective tax rate given product mix, geographic earnings mix and amortization of acquired intangibles.
- Execution of the stated product launches, Irish direct-sales initiative and Femcare integration plans, alongside regulatory and healthcare-reform risks.